DFTX
NASD Definium Therapeutics, Inc.$35.60 ↓ -0.02 (-0.06%) Trading Down from the previous close of $35.62
- YTD change
- +131.47%
- vs 20-day SMA
- -6.16%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
+15.04 (+73.08%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 28.4% away from all-time highs of $49.70
- DFTX is up 131% since the beginning of the year
- DFTX is up 131% over the past 12 months
- DFTX is down 7% over the past 1 month
- 9% of all DFTX investors are betting against DFTX
DFTX reads not so good: the 12-month move is +131.6%.
- Previous minute
- +$0.00
- Last hour
- +$0.15
- Last 5 days
- -6.83%
- vs 8-day SMA
- -4.33%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.